<DOC>
	<DOC>NCT00174200</DOC>
	<brief_summary>To assess the effect of risperidone 2 mg daily (QD) on the differential sensitivity of 2 spatial working memory tests (the GMLT and MDR) in non-agitated, drug-naive patients suffering from first-episode schizophrenia/schizophreniform disorder.</brief_summary>
	<brief_title>Study To Assess Differential Sensitivity Of 2 Spatial Working Memory Tests In Schizophrenics Treated With Risperidone</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Male or female, 18 to 50 years old, antipsychoticnaive, nonagitated patients diagnosed with firstepisode schizophrenia or schizophreniform disorder. Evidence or history of clinically significant medical or nonmedical impairment that, in the opinion of the investigator, would affect the safety of the patient or interfere with the evaluation of the trial results; Patients who have a history of substance (which included alcohol) dependence within 12 months or abuse within 3 months of enrollment, or tested positive for an illicit drug on the Screening urine toxicology test Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method of contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>